- Heat-resistant Covestro polycarbonate in medical technology
- Casing developed in close cooperation with Pentracor GmbH
LEVERKUSEN, 15-Apr-2016 — /EuropaWire/ — The blood plasma protein CRP (C-reactive protein), which is part of the endogenous immune system, is formed in the liver and passes into the bloodstream. In individuals suffering from infections, inflammation or tissue damage, the CRP level in blood is markedly elevated. Following a myocardial infarction, for example, selective lowering of such elevated CRP concentrations could reduce the infarction area and thus reduce the risk of heart failure developing as a consequence.
Pentracor, a medical technology company based in Hennigsdorf near Berlin, has developed an adsorber for selective removal of C-reactive protein in the context of extracorporeal apheresis called PentraSorb® CRP. The adsorber casing for the product is made of Covestro’s transparent, highly heat-resistant polycarbonate Apec®1745 and sterilized after filling.
Support right from the start
Throughout the development phase, Covestro provided support to its customer in the shape of materials knowledge but also in relation to the technical applications, starting with the choice of the polymer, which has to be transparent and heat resistant but also extremely dimensionally stable for this application. Apec®1745 is suitable for high-pressure steam sterilization and is mechanically highly robust. It is also approved for contact with body fluids. “So this polycarbonate was always the material of choice for this application,” explains Dr. Gunnar Janelt, Head of Production at Pentracor. “But we also really appreciated the development partnership with Covestro.”
The casing is injection-molded and the parts are then joined together with ultrasonic welding, with filter elements also being integrated at the same time. “This development is another example of how problems can be resolved with technical support,” says Markus Krieter, a specialist for medical technology applications in the Polycarbonates business unit at Covestro.
Covestro has been a dependable partner to the medical technology industry for many years, with long-term supply reliability and unchanged recipes.
With 2015 sales of EUR 12.1 billion, Covestro is among the world’s largest polymer companies. Business activities are focused on the manufacture of high-tech polymer materials and the development of innovative solutions for products used in many areas of daily life. The main segments served are the automotive, electrical and electronics, construction and the sports and leisure industries. Covestro, formerly Bayer MaterialScience, has 30 production sites around the globe and as of the end of 2015 employed approximately 15,800 people (full-time equivalents).
For more information go to www.covestro.com.
This press release may contain forward-looking statements based on current assumptions and forecasts made by Covestro AG. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Covestro’s public reports which are available on the Covestro website at www.covestro.com. Covestro assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
Dr. Frank Rothbarth
Covestro Deutschland AG
External Communications / Trade press
Phone: +49 214 6009 2536
Covestro Deutschland AG